• Dépistage, diagnostic, pronostic

  • Évaluation des technologies et des biomarqueurs

  • Système nerveux central

Effects of effective stereotactic radiosurgery for brain metastases on the adjacent brain parenchyma

Menée auprès de 16 patients présentant au total 19 métastases cérébrales traitées par radiochirurgie stéréotaxique (durée médiane de suivi : 39 mois), cette étude évalue l'intérêt d'une IRM métabolique et fonctionnelle pour détecter des lésions du parenchyme cérébral adjacent induites par les radiations

Background : To evaluate whether functional and metabolic MRI can detect radiation-induced alterations in the adjacent areas after effective stereotactic radiosurgery (SRS) for brain metastases. If confirmed, these techniques may be suited for monitoring the timely stratification of patients for neuroprotective treatments after irradiation.

Methods : Inclusion criteria were complete response, partial response, or stable disease on routine follow-up MR-scans. Multiparametric 3T-MRI was performed with diffusion-weighted imaging, dynamic susceptibility perfusion-weighted imaging, and two-dimensional proton MR-spectroscopy. Parameters were measured in the SRS-treated target and in the adjacent parenchyma up to both 0.75 cm and 1.5 cm from the target border.

Results : Nineteen lesions in sixteen consecutive patients met the inclusion criteria. The median follow-up time was 39 months (range, 10–142) with 41 multiparametric MR-examinations in total. We found low values of N-acetyl-aspartate up to 1.5 cm from the target borders of SRS (P = 0.043) associated with high values of choline (P = 0.004) at the end of the observation period. Lactate levels in the adjacent tissue declined over time, whereas continuously high apparent-diffusion-coefficient values were noted (P < 0.001).

Conclusion : Multiparametric MRI can depict radiobiological effects and their time course at a distance from the effectively treated site after SRS for brain metastases, even if conventional MRI findings are inconspicuous.

British Journal of Cancer , résumé, 2020

Voir le bulletin